CODEN [USA]: IAJPBB ISSN: 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

http://doi.org/10.5281/zenodo.2390865

Available online at: http://www.iajps.com *Review Article*

EARLY DIAGNOSIS OF CROHN'S DISEASE SYMPTOMS AND MANAGEMENT

[1]Nuha Abdulrahman Banjar,[2]Shahd Abdullah Abdulwahab , [3] Sara Edrees AlDrees,[4]Shejoun yazeed Binsaeed , [5]Norah S. Alajmi , [6]Habibah O Sardidi, [7] Malak A. Alsaif ,[8] Sahar S. Aldakhil,[9] Farah Saleh Aljoufi, [10] Abdulelah Yasser Fakieha,[11] Lujain hamad alfayez, [12]Ghadah Saad Alshehri, [13]Tamadr Mohammed Aldhahri

[1]Ibn Sina National college for Medical Studies,[2]Almaarefa university,[3]King Faisal university,[4]Almaarefa university,[5]King Saud bin Abdulaziz University for Health Sciences, [6]King Saud bin Abdulaziz University for Health Sciences,[7]King Saud bin Abdulaziz University for Health Science,[8]King Saud bin Abdulaziz University for Health Science.,[9]Tabuk university,[10]Ibn Sina National College for Medical Studies,[11]Almareefa university,[12]Ibn Sina National College for Medical Studies,[13]King Saud bin Abdulaziz University for Health Science.

Abstract:

Crohn's disease is a chronic, relapsing inflammatory condition of the gastrointestinal system. In this review we discuss the management methods and early diagnosis approaches. Recognition of the therapeutic possibility and associated unfavorable occasions is necessary both for providing benefit and for protecting patients from excessive dangers from these therapies. Targeted detailed search was conducted through databases; PubMed/Midline, and Embase, for these articles disusing the diagnosis of crohn's disease symptoms and management, with human subjects published up to end of 2018. Crohn's disease is a chronic IBD that can impact any type of section of the gastrointestinal tract. It is typically medically taken care of, but a significant percent of patients will need surgical procedure. The objectives of care are to cause and maintain a steroid-free remission, decrease the threat of issues and surgery, and likewise improve the total quality of life. The diagnosis of CD is a medical one and can be quite difficult considered that the here and now signs can be dangerous and nonspecific. Red flag symptoms that call for more assessment consist of weight-loss, bloody diarrhea, iron shortage, and night-time awakenings. In a similar way, considerable family history of IBD, unusual elevations in the c-reactive protein level, sedimentation rates, or various other acute-phase reactants (eg, ferritin and platelets), or reduced B 12 ought to prompt more investigation for feasible CD.

Corresponding author:
Nuha Abdulrahman Banjar,
Ibn Sina National college for Medical Studies

QR code

Please cite this article in press Nuha Abdulrahman Banjar et al., ***Early Diagnosis Of Crohn's Disease Symptoms And Management.,*** *Indo Am. J. P. Sci, 2018; 05(12).*

INTRODUCTION:

Crohn's disease (CD) was first characterized by Dr Burrill B. Crohn and colleagues in 1932 [1]. Together with ulcerative colitis (UC), it drops under the spectrum of chronic idiopathic inflammatory bowel disease (IBD) [1]. Crohn disease is a chronic disorder with a yearly occurrence varying from 3 to 20 situations per 100,000 [2]. The median onset of ailment is age 30 years and it has 2 tops, first in between age 20 and 30 years and after that a lesser top around age 50 years. Crohn illness is characterized by discontinuous skip sores impacting any part of the gastrointestinal tract from the mouth to the anus. The inflammation is typically transmural and on pathology granulomas might be present on biopsies [3]. Offering symptoms vary but can consist of looseness of the bowels, stomach discomfort, weight loss, queasiness, throwing up, and often fevers or chills [3]. The natural history of the disease is one of durations of remission and flares. There are numerous various phenotypes of disease including inflammatory, stricturing, and passing through. Patients can have 1 or even more of these illness phenotypes during the program of their ailment, and patients often progress from inflammatory to stricturing or permeating. However, there is no remedy for CD and most patients call for at least 1 surgical resection [3]. The objective of clinical treatment is to accomplish a steroid-free medical and endoscopic remission with the hopes of stopping problems and surgical procedure. Till just recently, drug choices were restricted to thiopurines, methotrexate (MTX), natalizumab, and anti-- tumor necrosis factor (anti-TNF) representatives. Of late, medicines with unique systems of activity have been accepted including a gut-selective antiintegrin (α4b7) prevention and a monoclonal antibody to IL-12/ IL-23.

Crohn's disease is a chronic, relapsing inflammatory condition of the gastrointestinal system. In this review we discuss the management methods and early diagnosis approaches. Recognition of the therapeutic possibility and associated unfavorable occasions is necessary both for providing benefit and for protecting patients from excessive dangers from these therapies.

METHODOLOGY:

Targeted detailed search was conducted through databases; PubMed/Midline, and Embase, for these articles disusing the diagnosis of crohn's disease symptoms and management, with human subjects published up to end of 2018, We restricted this search to only English language published articles.

DISCUSSION:

- **EPIDEMIOLOGY**

The prevalence of CD has an incidence of 3 to 20 situations per 100,000 [2]. Crohn ailment is a lot more common in the developed world, particularly in North America and Western Europe, though the incidence is climbing in Asia and South America [4]. There might be a slightly higher predominance of CD in females and it is much more usual in individuals of Ashkenazi Jewish origin than in non-Jews. The specific pathogenesis of CD is unidentified, although there are a number of genetic and ecological aspects that have been shown to increase the risk of the ailment and bring about the aberrant gut immune action feature of the illness [5].

- **CLINICAL FEATURES AND EXTRA MANIFESTATIONS**

CD is commonly defined by transmural inflammation of the intestine and can impact any type of part of the gastrointestinal tract from mouth to perianal area (Table 1). In regards to distribution of the ailment 25% of the patients have colitis just, 25% is ileitis only and 50% have ileocolitis. Roughly one-third of the patients have perianal involvement and 5- 15% have involvement of oral or gastroduodenal area [5]. Diarrhea is the most usual symptom of dynamic CD as a result of reduced water absorption and raised secretion of electrolytes. Various other reason for diarrhea in CD consist of small bowel bacterial overgrowth (SBBO) generally in obstructive illness and bile acid diarrhea as a result of diseased/resected bowel. In Ileocolitis, the signs imitate acute appendicitis with ideal lower quadrant stomach distress, high temperature and diarrhea. Considerable disease could result in malabsorption and steatorrhea. Reduced grade fever could be a symptom of inflammatory process in CD, whereas top-quality high temperature often recommends intra-abdominal abscess or contagious process. About 10 - 20% weight reduction prevails in patients identified with CD due to decreased oral intake and malabsorption [6]. The common extraintestinal manifestations (EIM) in CD consist of big joint arthritis, uveitis, iritis, episcleritis, erythema nodosum and pyoderma gangrenosum.

Table 1. Location of Crohn's Disease and Associated Symptoms [5-6] .

LOCATION	*SYMPTOMS*	*COMMENTS*	*FREQUENCY (%)*	*COMMON DIAGNOSTIC TESTING*
Ileum and colon	Diarrhea, cramping, abdominal pain, weight loss	Most common form	35	Colonoscopy with ileoscopy, CT enterography, biopsy
Colon only	Diarrhea, rectal bleeding, perirectal abscess, fistula, perirectal ulcer	Skin lesions and arthralgias more common	32	Colonoscopy with ileoscopy, CT enterography, biopsy
Small bowel only	Diarrhea, cramping, abdominal pain, weight loss	Complications may include fistula or abscess formation	28	Colonoscopy with ileoscopy, CTenterography, capsule endoscopy, small bowel follow-through, enteroscopy, biopsy, magnetic resonance enterography
Gastroduodenal region	Anorexia, weight loss, nausea, vomiting	Rare form	5	Esophagogastroduodenoscopy, small bowel follow-through, enteroscopy

- **DIAGNOSTIC STUDIES**

Laboratory testing

Research laboratory tests serve for identifying Crohn's illness, examining disorder activity, recognizing issues, and monitoring response to treatment. Preliminary screening usually includes white blood cell count; platelet count; measurement of hemoglobin, hematocrit, blood urea nitrogen, creatinine, liver enzymes, and C-reactive protein; and erythrocyte sedimentation rate. Stool culture and screening for Clostridium difficile toxic substance should be thought about [7]. Existence of antibodies to Escherichia coli outer membrane porin and Saccharomyces cerevisiae is suggestive of Crohn's disease, whereas perinuclear antineutrophil cytoplasmic antibody is more symptomatic of ulcerative colitis [8].

Succeeding screening might include measurement of iron, ferritin, overall iron-binding ability, vitamin B12, folate, albumin, prealbumin, calcium, and vitamin D to keep track of typical complications. Fecal lactoferrin and calprotectin are surrogate markers for digestive tract inflammation and may aid compare inflammatory conditions and irritable digestive tract syndrome [9]. An elevated fecal calprotectin level dependably shows relapse in patients with Crohn's disease (sensitivity of 80 percent; uniqueness of 90.7 percent; favorable probability proportion = 1.9; adverse chance ratio = 0.04) [9].

Endoscopy and related inverstigations

Colonoscopy with ileoscopy and biopsy is important in the diagnosis of Crohn's illness at the junction of the ileum and colon [7]. Particular endoscopic findings consist of skip sores, cobblestoning, ulcerations, and strictures. Histology may show neutrophilic swelling, noncaseating granulomas, Paneth cell metaplasia, and intestinal tract villi blunting. Various other diagnostic examinations valuable in the medical diagnosis of little bowel Crohn's disease include capsule endoscopy, computed tomography enterography, magnetic vibration enterography, and little bowel follow-through (Table 2) [10]. Capsule endoscopy should be stayed clear of in patients with tiny bowel strictures because pill retention might happen. Esophagogastroduodenoscopy is suggested in patients with upper gastrointestinal signs; asymptomatic patients with iron shortage anemia; and patients with active Crohn's disorder who have a regular colonoscopy [7].

Table 2. Contrast of Various Diagnostic Tests for Crohn's Disease [7],[10].

TEST	*COMMENT*
Capsule endoscopy	Better yield for nonstricturing small bowel Crohn's illness than small bowel follow-through and colonoscopy with ileoscopy; capsule retention possible with little bowel stricture
Colonoscopy with ileoscopy	Direct visualization of inflammation, fistula, or stricture of terminal ileum and colon; capacity to obtain biopsies from the ileum and colon
Computed tomography enterography	Permits visualization of the bowel wall and lumen; subjects patient to ionizing radiation
Computed tomography	Discloses intraintestinal inflammation and extraintestinal symptoms; subjects patient to ionizing radiation
Magnetic resonance enterography	Allows visualization of the bowel and lumen; costly; no ionizing radiation
Magnetic resonance imaging	Reveals intraintestinal inflammation and extraintestinal manifestations without radiation
Scintigraphy	Makes use of radiolabeled leukocytes to identify bowel inflammation and to estimate disease level and activity; role in clinical method is restricted
Small bowel follow-through	Radiographic testing of small bowel after ingestion of contrast medium (barium)
Ultrasonography	Identifies growth in vascular flow, abscess, sinus tracts, and lymphadenopathy

- **TREATMENT**

The treatment of CD depends on ailment seriousness, area of ailment, and subtype of disease (ie, inflammatory, stricturing, or passing through). We now additionally try to determine who is at risk for hostile CD and that may call for earlier and extra aggressive treatments. Risk variables for aggressive ailment activity include age of medical diagnosis less than 30 years, substantial structural involvement, perianal disorder, deep ulcers, prior surgical treatment, and stricturing and/or passing through disease [11]. Among the most significant difficulties related to CD is that after 20 years of disorder task 80% of patients will certainly need a surgical procedure and around 30% will require surgery within 5 years of medical diagnosis [12]. Although the goal of medical treatment is to preserve remission without the requirement for surgical treatment, when stricturing and/or fistulizing difficulties occur, surgery may be needed. However, due to the fact that surgery is not alleviative for CD, several patients will certainly require several surgical treatments over their lifetime [12].

There are a number of various drugs used to treat CD. Mesalamine has actually been evaluated in a variety of studies but has actually not been revealed to successfully cause or maintain remission in CD. The perceived advantage of mesalamine is most likely pertaining to its safety profile. Antibiotics are additionally utilized in CD, however the proof supporting their usage is likewise limited [13]. The major function of prescription antibiotics is to treat the suppurative or perianal issues of CD. The immunosuppressants azathioprine (AZA)/ mecaptopurine (MP) and MTX have actually been made use of for many years to treat CD however due to sluggish beginning of action they are generally made use of to preserve remission. However, more

current researches question the total effectiveness of AZA/MP as monotherapy and their use in very early CD [14]. More lately, these drugs are utilized in mix with anti-TNF drugs to decrease their immunogenicity and rise anti-TNF medication concentrations. The essential of therapy for CD has been anti-TNF agents. A lot more just recently approved drugs are monoclonal antibodies directed versus certain integrins (α4 or α4b7) or interleukins (IL-12/ IL-23). The first antiintegrin authorized for CD was natalizumab, however this is connected with progressive multifocal leukoencephalopathy (PML), a deadly brain infection [15]. Vedolizumab is a gut-selective antiintegrin that has not been associated with PML and is utilized mostly to keep remission in moderate to extreme CD with only modest performance at induction of remission [16]. In contrast, one of the most just recently approved representatives, ustekinumab, an IL-12/ IL-23 inhibitor, has actually been shown to be as effective as anti-TNF treatment at generating and preserving remission in modest to severe CD [17].

Eventually, the goal of medical treatment is to generate and maintain a steroid-free clinical remission, avoid issues and surgical procedure, and boost the patient's lifestyle. For normal medicine, issues, and keeping an eye on referrals, see Table 3.

Table 3. Medications, Monitoring, and Adverse Events [11-17] .

Medications	**Drugs**	**Available routes**	**Efficacy**	**Routine testing recommended**	**Adverse events to be aware of (not all inclusive)**
5-Aminosalycilates	Mesalamine Balsalazide Sulfasalazine	Oral Rectal	Induction and maintenance but not FDA approved for Crohn disease	Cr ± urinalysis CBC, LFTs	Headache Nausea Diarrhea Paradoxical worsening of symptoms Interstitial nephritis Hemolytic anemia, leukopenia, hepatitis
Corticosteroids	Prednisone Budesonide Methylprednisolone	Oral Rectal IV	Induction only	Consider checking hemoglobin A_{1c} and vitamin D levels If prolonged steroid >3 mo: DEXA scan and ophthalmology evaluation	Osteopenia/porosis Avascular necrosis Serious infection Weight gain Insomnia Mood changes Delirium Cataracts Glaucoma Skin changes Delayed wound healing Adrenal insufficiency

Medications	**Drugs**	**Available routes**	**Efficacy**	**Routine testing recommended**	**Adverse events to be aware of (not all inclusive)**
Thiopurines	Azathioprine Mercaptopurine	Oral	Maintenance	TPMT enzyme activity or genetics before initiation CBC, LFTs Skin examinations Yearly Pap smear in women	Nausea Vomiting Transaminitis Bone marrow suppression Pancreatitis Infection Non-Hodgkin lymphoma Nonmelanoma skin cancer Cervical dysplasia
Methotrexate [b]	Methotrexate	Subcutaneous or intramuscular (limited efficacy of oral route)	Induction and maintenance	CBC, LFTs	Infection Cytopenias Transaminitis Cirrhosis Nausea/vomiting Flu-like symptoms Oral ulcers Pulmonary toxicity Contraindicated in pregnancy
Anti-TNF	Infliximab Adalimumab Certolizumab pegol	IV Subcutaneous	Induction and maintenance	Latent TB and hepatitis B before initiation CBC, LFTs Skin examinations	Infusion/injection-site reaction Infection Non-Hodgkin lymphoma (mostly if combined with a thiopurine) HSTC-L (if combined with a thiopurine) Melanoma Reactivation of latent TB and hepatitis B Drug-induced lupus erythematosus Demyelinating disease Psoriasform and eczema reactions Worsening of CHF

Medications	Drugs	Available routes	Efficacy	Routine testing recommended	Adverse events to be aware of (not all inclusive)
Adhesion molecule inhibitors	Natalizumab Vedolizumab	IV	Induction and maintenance	Natalizumab: JC virus checking before initiation and yearly monitoring for JC virus Vedolizumab and natalizumab: Consider CBC	Infusion reactions Infection Nasopharyngeal polyps PML (natalizumab only with positive JC virus)
IL-12/IL-23 inhibitors	Ustekinumab	IV/subcutaneous	Induction and maintenance	Latent TB before initiation Consider CBC, LFTs	Infusion reactions Skin cancer Reversible posterior leukoencephalopathy TB

Anti-TNF = anti–tumor necrosis factor; CBC = complete blood cell count; CHF = congestive heart failure; Cr = creatinine; DEXA = dual energy-x-ray absorptiometry; FDA = Food and Drug Administration; HSTLC = hepatosplenic T-cell lymphoma; IV = intravenous; JC = John Cunningham; LFT = liver function test; Pap = papanicolaou; PML = progressive multifocal leukoencephalopathy; TB = tuberculosis; TPMT = thiopurine methyltransferase.

- **SURGERY**

Many patients with CD will certainly undertake surgery during the program of their illness [18]. Surgery is shown in a variety of scenarios including stricturing CD with obstructive symptoms, fistulizing or perianal CD with transmittable problems or concerns associated with the drainage of the fistula, failure of medical therapy, steroid dependence, dysplasia, or cancer [18]. The exact procedure depends on the underlying indicator for the surgery.

Stricturing CD

No clinical treatment reverses the fibrostenotic changes that cause strictures. In patients that have recurring obstructive signs and symptoms, surgical resection of the stricture may be suggested [25]. Because surgical treatment is not alleviative, the goal is to remove the tiniest amount of bowel possible and perform a primary anastomosis. When there are numerous strictures, elimination of every one of them may not be viable. In these instances, the most noticeable stricture might be resected while the others may either be expanded intraoperatively or a stricturoplasty might be carried out [18], [25].

Fistulizing CD

For enteroenteric fisulae, as long as the fistula is not triggering a direct issue, it is rarely intervened upon. However, in cases of enterovesicular fistulae, enterovaginal fisulae, or enterocutaneous fistulae, bowel resection and fistulotomy are often called for [19]. Also, if a sinus system is present and an abscess kind, after that radiologic or surgical water drainage of the abscess might be required also [19].

Perianal CD

Perianal CD can present as an anal fissure, perianal fistula, or perirectal abscess. Both perianal fistula and abscess often need surgical treatment with drainage and placement of a seton. Anal fissures are usually dealt with medically with therapy for CD however if they do not respond after that a fissurotomy can be thought about or in many cases botulinum toxic substance injections might likewise be used [20].

- **POSTOPERATIVE MEDICAL THERAPY**

Unfortunately, around 50% of patients will create a clinical recurrence within 5 years of their surgery and as lots of as 40% will call for a second surgical procedure within 10 years [3]. Preferably, medication treatment is used to avoid this medical reoccurrence. However, the general effectiveness of using pharmacologic treatment to prevent medical reappearance of CD complying with surgery is uncertain [21]. The most robust data are with using anti-TNF therapy [22]. Typically, patients will

certainly undergo a colonoscopy 6 to 12 months after surgical procedure to assess for endoscopic reoccurrence and to execute a Rutgers racking up system to predict the probability of clinical reoccurrence in the next 1 to 5 years (Table 4) [23]. Nevertheless, in patients who are at high risk of early medical recurrence (Table 5), some doctors decide to position patients on immediate postoperative medicine [24]. No matter, continuous colonoscopic evaluation for recurrence is advised.

Table 4. Rutgeerts Score Assessment [23].

i0	No lesions seen	Low risk: 80%-85% in remission in 3 y
i1	≤5 aphthous ulcers	Low risk: 80%-85% in remission in 3 y
i2	>5 aphthous ulcers with normal mucosa between lesions or lesions confined to ileocolonic anastomosis that is <1 cm in length	15%-20% chance of recurrence in 3 y
i3	Diffuse aphthous ileitis with diffusely inflamed mucosa	40% chance of recurrence in 3 y
i4	Diffuse inflammation with large ulcers, nodules, and/or narrowing	90% chance of recurrence in 3 y

Table 5. Risk Factors for Clinical Recurrence After Surgery [24]

Risk factors
Stricturing or fistulizing disease Active tobacco abuse Prior intestinal resection (especially >50 cm) Early age of onset of disease Perianal disease

CONCLUSION:

Crohn's disease is a chronic IBD that can impact any type of section of the gastrointestinal tract. It is typically medically taken care of, but a significant percent of patients will need surgical procedure. The objectives of care are to cause and maintain a steroid-free remission, decrease the threat of issues and surgery, and likewise improve the total quality of life.

The diagnosis of CD is a medical one and can be quite difficult considered that the here and now signs can be dangerous and nonspecific. Red flag symptoms that call for more assessment consist of weight-loss, bloody diarrhea, iron shortage, and night-time awakenings. In a similar way, considerable family history of IBD, unusual elevations in the c-reactive protein level, sedimentation rates, or various other acute-phase reactants (eg, ferritin and platelets), or reduced B 12 ought to prompt more investigation for feasible CD.

Diagnosis and management of Crohn's disease is based on clinical symptoms and signs integrated with research laboratory examinations, endoscopy and imaging methods. Endoscopy is the gold requirement for the assessment of patients with Crohn's disease. Nonetheless, a right diagnosis requires radiological evaluations to specify the extent and phase of the ailment and specially to detect transmural problems consisting of fistulae, abscesses and phlegmons. Computed tomography (CT) and magnetic resonance imaging (MRI) are currently shown in the research study of the gastrointestinal tract. Diagnostic level of sensitivity and specificity of these two methods are comparable and both additionally present certain restrictions. CT is extensively made use of and execution time is short, whereas MRI is much less common and calls for a longer execution time. Over the past decade, ultrasound (US) has gradually been introduced to support clinical exam in the diagnosis and monitoring of patients with Crohn's disease.

REFERENCE:

1. Wilks S.: Morbid appearances in the intestine of Miss Bankes. London Med Times Gazette 1859; 2: pp. 264.
2. Molodecky N.A., Soon I.S., Rabi D.M., et al: Increasing incidence and prevalence of the

inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: pp. 46-54.
3. Cheifetz A.S.: Management of active Crohn disease. JAMA 2013; 309: pp. 2150-2158
4. Rieder F., Latella G., Magro F., et al: European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease. J Crohns Colitis 2016; 10: pp. 873-885.
5. Burgmann T., Clara I., Graff L., et al: The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis–how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006; 4: pp. 614-620.
6. Baumgart D.C., and Sandborn W.J.: Crohn's disease. Lancet 2012; 380: pp. 1590-1605.
7. Stange EF, Travis SP, Vermeire S, et al.; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. *Gut*. 2006; 55(suppl 1):i1–i15.
8. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004;99(11):2235–2241.
9. Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010;22(3):340–345.
10. Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008;68(2):255–266.
11. Dassopoulos T., Sultan S., Falck-Ytter Y.T., Inadomi J.M., and Hanauer S.B.: American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti–TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013; 145: pp. 1464-1478
12. Bernstein C.N., Loftus E.V., Ng S.C., Lakatos P.L., and Moum B.: Hospitalisations and surgery in Crohn's disease. Gut 2012; 61: pp. 622-629
13. Gomollón F., Dignass A., Annese V., et al: 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016, part 1: Diagnosis and Medical Management. J Crohns Colitis 2017; 11: pp. 3-25
14. Panés J., López-SanRomán A., Bermejo F., et al: Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013; 145: pp. 766-774
15. Sandborn W.J., Colombel J.F., Enns R., et al: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: pp. 1912-1925
16. Sandborn W.J., Feagan B.G., Rutgeerts P., et al: Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: pp. 711-721
17. Sandborn W.J., Gasink C., Gao L.L., et al: Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: pp. 1519-1528
18. Yamamoto T., and Watanabe T.: Surgery for luminal Crohn's disease. World J Gastroenterol 2014; 20: pp. 78-90
19. Gionchetti P., Dignass A., Danese S., et al: 3. EUROPEAN Evidence-based consensus on the diagnosis and management of Crohn's disease 2016, part 2: surgical management and special situations. J Crohns Colitis 2017; 11: pp. 135-149
20. Schwartz D.A., Ghazi L.J., and Regueiro M.: Guidelines for medical treatment of Crohn's perianal fistulas: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2015; 21: pp. 737-752
21. De Cruz P., Kamm M.A., Hamilton A.L., et al: Crohn's disease management after intestinal resection: a randomised trial. Lancet 2015; 385: pp. 1406-1417
22. Herfarth H.H.: Anti–tumor necrosis factor therapy to prevent Crohn's disease recurrence after surgery. Clin Gastroenterol Hepatol 2014; 12: pp. 1503-1506
23. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., and Hiele M.: Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: pp. 956-963
24. Buisson A., Chevaux J.B., Allen P.B., Bommelaer G., and Peyrin-Biroulet L.: Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther 2012; 35: pp. 625-633
25. Rieder F., Latella G., Magro F., et al: European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease. J Crohns Colitis 2016; 10: pp. 873-885.